Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities

Abstract Nanomedicine has become an important translational platform in oncology by enabling altered pharmacokinetics, controlled exposure, reduced systemic toxicity, intracellular delivery of nucleic acids, and improved handling of complex therapeutic payloads. Early cancer nanomedicines, including pegylated liposomal cytotoxics and albumin-bound drug products, demonstrated that nanoscale formulation design could improve the clinical utility of established anticancer agents. More recently, lipid nanoparticles, RNA therapeutics, individualized neoantigen vaccines, gene-regulatory approaches, and immune-modulating delivery systems have expanded the role of nanoparticles from passive drug carriers to programmable oncology platforms. This narrative review examines the developmental evolution of cancer-focused pharmaceutical nanoparticles, with emphasis on liposomes, lipid nanoparticles (LNPs), albumin-bound systems, polymeric particles, polymeric micelles, nanocrystals, nanoemulsions, solid lipid nanoparticles, inorganic particles, extracellular vesicles, and hybrid delivery technologies. Each platform class is treated systematically, covering representative approved products, formulation characteristics, route of administration, clinical evidence, and the specific development risks that limit it. There view connects platform design with oncology-specific barriers, including tumor heterogeneity, variable enhanced permeability and retention (EPR) effects, dense extracellular matrix, abnormal tumor vasculature, mononuclear phagocyte clearance, protein-corona formation, endosomal escape, immune activation, and the difficulty of translating animal tumor models into clinical benefit. These barriers are organized as a sequential delivery cascade, and the behavior of each platform class is compared step by step rather than described as a set of universal phenomena. Nanoparticle candidates that accumulated well in preclinical tumors but failed in clinical trials are examined alongside approved products, because the contrast between the two is where most of the transferable lessons sit. A product-development perspective is used to discuss critical quality attributes (CQAs), manufacturing scalability, potency testing, sterility strategy, stability, release methods, regulatory expectations, commercial feasibility, and clinical differentiation. A development-to-translation framework is proposed for comparing cancer nanomedicine platforms across formulation maturity, analytical maturity, manufacturing maturity, biological rationale, clinical evidence, regulatory readiness, and commercial feasibility; regulatory and commercial maturity are scored separately, the criteria behind each level are defined explicitly, and the resulting rankings are presented as a heuristic aid to discussion rather than a validated quantitative metric. Future progress in oncology nanomedicine will depend not only on novel materials or targeting claims, but also on disciplined product design, biologically meaningful potency assays, scalable manufacturing, patient-selection strategies, and clear integration with precision oncology.